新型烯二炔类抗肿瘤抗生素力达霉素的研究进展  

Advances in the research of lidamycin,an enediyne antitumor antibiotic

作　　者：马迪[1] 洪斌[1] 

机构地区：[1]中国医学科学院中国协和医科大学医药生物技术研究所,北京100050

出　　处：《中国抗生素杂志》2007年第1期11-16,共6页Chinese Journal of Antibiotics

摘　　要：带有烯二炔结构发色团的抗肿瘤抗生素力达霉素对肿瘤细胞有极强的杀伤力,是近年来发现的抗肿瘤活性较强的化合物之一,在肿瘤的化学治疗方面有良好的应用前景。本文介绍力达霉素的分子结构与生物合成、化学合成、分子作用机制与抗肿瘤活性、单克隆抗体高效偶联物、组合生物合成等方面研究的最新进展。Lidamycin is an enediyne antitumor antibiotic with potent cytotoxicity against varieties of cancer cell lines. It is considered as one of the most effective natural products with antitumor biological activity found in recent years and is expected to have great potential on the chemotherapy of cancers. This article reviews the recent research progress of lidamycin, focusing on its molecular structure, biosynthesis, molecular mechanism of action, antitumor effects, conjugation with monoclonal antibody, as well as the prospective of combinatorial biosynthesis of this class of antibiotics.

关 键 词：力达霉素 烯二炔类抗生素 抗肿瘤 

分 类 号：R979.14[医药卫生—药品]